



A scalable and flexible future for gene therapy production

Branden Salinas, PhD, Head of MSAT, Umoja Biopharma Carissa Marak, AIA, LEED AP BD+C, CRB Consulting Engineers

What is Umoja Biopharma?


Our mission is to advance and improve access to immunotherapy by retooling the patient's immune system in vivo, freeing them from the burden of cancer in their daily lives

To this end Umoja has raised >260 MUSD, which enables the construction of a development and manufacturing facility

Autologous CAR-T therapy—20+ days vein-to-vein per patient Collection of patient PBM cells Transport to manufacturing lab CAR transfer by viral vector CAR-T cells Transport to treatment center Transfuse T cell therapy CAR-T cells reach tumor cell therapy Transfuse T cell therapy

Umoja VivoVec — one manufacturing process treats thousands of patients

Patient conditioning: immunodepletion via chemotherap






Umoja's novel lentiviral drug product

Vivovec is a novel lentivirus that brings the power of CAR-T therapy to solid tumors

Controlling the supply chain for lentivirus drug product is critical





The need for speed and flexibility

The Needs:

Speed to Phase 1 and VivoVec proof-of-concept is a top priority

Quick transition to other modalities or pivotal/commercial

Platform variety and anticipating future needs

The Approach:

- Design and build a facility proactively, while the process is in development
- Co-locate the technical know-how and operational capabilities in one cross-functional space



Supporting Umoja's Culture

Diversity, Equity and Inclusion

Hire, develop, engage and retain top talent

Think Big, Plan for Success

Environmental Impact

Supporting the growth of Biotech and Cell & Gene Therapy in Colorado






Architectural Drivers

Flexibility

Speed

Quality


Sustainability






Facility Overview

- Existing Core & Shell
- Phased Construction
- Location between Denver
 & Boulder, CO









Flexibility

- Site Selection
- Master Planning
- Spatial considerations for future scales
- Installing and sizing utilities upfront for future
- Ease of construction for future expansion as production continues





Facility Overview Mappinges





Facility Overview Mechanicalnities






Flexibility PRODUCTION HALLWAY M127 AL-OUT AL-OUT LABEL/INSPECT AL-OUT EQ WASH M116 M120 M111 M106 VECTOR PRODUCTION FORM/FILL CELL EXP/CB M119 M110 EC/CONSUM STOR CLEAN EQUIP M104 PAL-IN MAL-IN MAL-IN PAL-IN PAL-IN MAL-IN MISC. 口中 M113 WASTE/AL M109 M121 M118 M108 M123 SOLUTION STAGING / PRODUCTION HALLWAY M128



Flexibility

- Each MFG suite on its own segregated HVAC system
 - Provides ease of changing airflows, positive and negative pressure per individual suite





Speed

- -ONEsolution, integrated project delivery
- -Phased project approach, prioritizing labs for process development
- -Design-Assist with early Trade Partners
- -Planning for clinical MFG/QC space on assumptions
- -Flexible design process



CONCEPT 5/21 → SUBSTANTIAL COMPLETION 7/22 92,000SF PD/QC LABS, WH



Quality



a facility to match the product



Sustainability

- WELL Building Certification Silver
 - Health and Wellbeing of employees
- **DEI Project Execution**
 - Commitment to entire project team mental and physical health
- Serving the community together
 - Stewardship and meaningful contribution to community context
- Zero Carbon Emissions and Combustion by 2031
 - Electric boilers
 - Carport and roof mounted onsite renewable energy generation
 - **AWW Heat Pump Chillers**













WATER

NOURISHMENT

LIGHT

MOVEMENT













THERMAL COMFORT

MATERIALS

MIND

COMMUNITY





Connecting Phari

Conclusion

Umoja: Unity - To strive for and maintain unity in the family, community, nation, and race.



